A stem cell–based therapy initially developed at Memorial Sloan Kettering Cancer Center (MSK) may lead to a new treatment for advanced Parkinson's disease, according to results from a phase 1 clinical ...

Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of ...

Virat Kohli, the first Indian athlete to sign a Rs 100 crore deal with Puma in 2017, has ended the partnership. He reportedly ...

With its ability to specifically inhibit the mutant IDH1 enzyme, TIBSOVO addresses an unmet need in personalized cancer treatment, offering new hope for patients with limited options. As clinical ...

The National Board of Examinations in Medical Sciences (NBEMS) is set to reopen the registration window for the National Eligibility-cum-Entrance Test for Master of Dental Surgery (NEET MDS) 2025 ...

Tencent recently invested €1.16 billion ($1.25 billion) in the new Ubisoft subsidiary focused on managing major franchises ...

Carlos Bais and David Matly to CSO and President, respectively. Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.) Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Max, formerly known as HBO Max, officially has a new logo on Sunday night, March 30. The new logo for Warner Bros. Discovery's steaming platform was unveiled on Sunday evening. The new logo gives ...

WARRINGTON, United Kingdom, March 25, 2025 (GLOBE NEWSWIRE) -- MDS Global, a leading provider of Business Support Systems (BSS) for digital telcos, is delighted to announce a new strategic ...

The University of South Florida's Institute of Applied Engineering (IAE) stands as a distinctive and impactful organization, addressing a pressing concern within the government with notable success ...